11 Jan 2019 Research
Lymphoma: Understanding relapse and treatment resistance
What is this research looking at?
Our immune system is remarkable. It is made up of many different types of immune cells that work together to protect the body from infection by pathogens such as bacteria, viruses and parasites.
We are investigating what happens when a certain type of cell in the immune system, known as B cells, starts growing out of control and develops into blood cancers such as leukaemia, lymphoma and myeloma.
We want to know what happens when B cells mature normally from precursor cells in the bone marrow and discover what has gone wrong when they turn into cancer cells instead.
Considerable success has been achieved in the treatment of lymphoma. However, a significant unmet need remains: roughly 40% of patients either do not respond to treatment or the condition recurs after treatment. Currently, our ability to predict which patients will fail treatment is poor.
By taking a detailed look at B cells as they develop and specialise, we can spot small groups of dangerous cells that are particularly likely to turn into cancer and identify the genetic faults that drive B cells to grow out of control.
We are using our knowledge to create new models for the development of B cells and blood cancers in the lab, so we can find new ways to treat or even prevent these deadly diseases.
Our research uses a model of lymphoma to test the response to treatments and development of resistance. A main advantage of the model is that we can interrogate these questions on a well-defined scenario and can perform iterative tests and predictions. Further, the model generated in this project will allow initial testing of novel treatments.
What could this mean for people with leukaemia?
This research could inform the medical decision of when to use combination and novel therapies for patients with a higher probability of developing resistance to standard treatment, alongside bringing safer treatments to patients.
Official project title: Development of a model system to study diffuse large B cell lymphoma clonal evolution
Related posts
1 August 2022
Pedalling pair’s crazy peaks challenge to stop leukaemia cutting short the lives of beloved mums
Leukaemia UK supporter, Alistair, who lost is mum to leukaemia less than a year ago, is setting out on an extreme fundraising challenge. Alistair, who is from Lincoln, and his…
11 January 2019
Lymphoma: Understanding relapse and treatment resistance
Dr Dinis Calado, The Francis Crick Institute and Project Grant Holder
14 March 2023
Percy & Nell says Pants to Leukaemia with bespoke charity collaboration
Independent clothing brand Percy & Nell has produced a unique range of sweatshirts, t-shirts, beanies and tote bags, with all profits going to Leukaemia UK. The collaboration comes off the…
4 June 2022
Leukaemia UK is looking for volunteers for their Patient Experience Advisory Panel
Leukaemia UK is committed to championing advancements in better treatments and care for all. We want to ensure the needs of patients are at the heart of everything we do, and that the voices of people affected by leukaemia and related conditions are being heard. That is why we are setting up a Patient Experience Advisory Panel.